Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study

BEAM conditioning regimen (carmustine [BCNU], etoposide, cytarabine, and melphalan) has been widely used for autologous stem cell transplantation in patients with relapsed or refractory lymphoma. However, BCNU-associated toxicities have prompted research to explore other options. This study aimed to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Naif I. AlJohani, Momen Nasani, Hosam E. Ahmed, Jalil Ur Rehman, Azhar Nawaz, Zayed Alzahrani, Bassim Albeirouti
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Autologous stem cell transplant BCNU Bendamustine Carmustine Lymphoma Toxicity Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/cf7e1fd1ad474579be58f4b48c8d461b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:cf7e1fd1ad474579be58f4b48c8d461b
record_format	dspace
spelling	oai:doaj.org-article:cf7e1fd1ad474579be58f4b48c8d461b2021-12-02T05:00:00ZDose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study1658-387610.1016/j.hemonc.2020.11.003https://doaj.org/article/cf7e1fd1ad474579be58f4b48c8d461b2021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1658387620301758https://doaj.org/toc/1658-3876BEAM conditioning regimen (carmustine [BCNU], etoposide, cytarabine, and melphalan) has been widely used for autologous stem cell transplantation in patients with relapsed or refractory lymphoma. However, BCNU-associated toxicities have prompted research to explore other options. This study aimed to assess the feasibility of bendamustine as an alternative to BCNU. We compared 71 patients who received either bendamustine (Benda-EAM group) or BCNU (BEAM group) conditioning. Considering previous reports of increased cardiotoxicity, nephrotoxicity, and mucositis, we adopted a lower bendamustine dose of 160 mg/m2/day administered for 2 days. There was no increase in nephrotoxicity and cardiotoxicity. Further, positive results were also obtained for neutrophil and platelet engraftment, appearing earlier in patients treated with Benda-EAM (10 vs. 14 days and 16 vs. 27 days, respectively). However, caution is warranted because an increased frequency of Grade 3 mucositis was observed in the Benda-EAM group (82.4% vs. 48%). This was accompanied by an increased need for parenteral nutrition. Despite the lower dose of bendamustine, the overall and progression-free survival rates were comparable between the Benda-EAM and BEAM groups. In conclusion, a lower dose of bendamustine may be an attractive alternative to BCNU as a tolerable treatment modality for patients with relapsed/refractory lymphoma.Naif I. AlJohaniMomen NasaniHosam E. AhmedJalil Ur RehmanAzhar NawazZayed AlzahraniBassim AlbeiroutiElsevierarticleAutologous stem cell transplantBCNUBendamustineCarmustineLymphomaToxicityDiseases of the blood and blood-forming organsRC633-647.5Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENHematology/Oncology and Stem Cell Therapy, Vol 14, Iss 4, Pp 327-335 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Autologous stem cell transplant BCNU Bendamustine Carmustine Lymphoma Toxicity Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Autologous stem cell transplant BCNU Bendamustine Carmustine Lymphoma Toxicity Diseases of the blood and blood-forming organs RC633-647.5 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Naif I. AlJohani Momen Nasani Hosam E. Ahmed Jalil Ur Rehman Azhar Nawaz Zayed Alzahrani Bassim Albeirouti Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study
description	BEAM conditioning regimen (carmustine [BCNU], etoposide, cytarabine, and melphalan) has been widely used for autologous stem cell transplantation in patients with relapsed or refractory lymphoma. However, BCNU-associated toxicities have prompted research to explore other options. This study aimed to assess the feasibility of bendamustine as an alternative to BCNU. We compared 71 patients who received either bendamustine (Benda-EAM group) or BCNU (BEAM group) conditioning. Considering previous reports of increased cardiotoxicity, nephrotoxicity, and mucositis, we adopted a lower bendamustine dose of 160 mg/m2/day administered for 2 days. There was no increase in nephrotoxicity and cardiotoxicity. Further, positive results were also obtained for neutrophil and platelet engraftment, appearing earlier in patients treated with Benda-EAM (10 vs. 14 days and 16 vs. 27 days, respectively). However, caution is warranted because an increased frequency of Grade 3 mucositis was observed in the Benda-EAM group (82.4% vs. 48%). This was accompanied by an increased need for parenteral nutrition. Despite the lower dose of bendamustine, the overall and progression-free survival rates were comparable between the Benda-EAM and BEAM groups. In conclusion, a lower dose of bendamustine may be an attractive alternative to BCNU as a tolerable treatment modality for patients with relapsed/refractory lymphoma.
format	article
author	Naif I. AlJohani Momen Nasani Hosam E. Ahmed Jalil Ur Rehman Azhar Nawaz Zayed Alzahrani Bassim Albeirouti
author_facet	Naif I. AlJohani Momen Nasani Hosam E. Ahmed Jalil Ur Rehman Azhar Nawaz Zayed Alzahrani Bassim Albeirouti
author_sort	Naif I. AlJohani
title	Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study
title_short	Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study
title_full	Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study
title_fullStr	Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study
title_full_unstemmed	Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study
title_sort	dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: a retrospective single-center study
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/cf7e1fd1ad474579be58f4b48c8d461b
work_keys_str_mv	AT naifialjohani doseadjustedbendamustineasareplacementforcarmustineinautologousstemcelltransplantconditioningforpatientswithrelapsedlymphomaaretrospectivesinglecenterstudy AT momennasani doseadjustedbendamustineasareplacementforcarmustineinautologousstemcelltransplantconditioningforpatientswithrelapsedlymphomaaretrospectivesinglecenterstudy AT hosameahmed doseadjustedbendamustineasareplacementforcarmustineinautologousstemcelltransplantconditioningforpatientswithrelapsedlymphomaaretrospectivesinglecenterstudy AT jalilurrehman doseadjustedbendamustineasareplacementforcarmustineinautologousstemcelltransplantconditioningforpatientswithrelapsedlymphomaaretrospectivesinglecenterstudy AT azharnawaz doseadjustedbendamustineasareplacementforcarmustineinautologousstemcelltransplantconditioningforpatientswithrelapsedlymphomaaretrospectivesinglecenterstudy AT zayedalzahrani doseadjustedbendamustineasareplacementforcarmustineinautologousstemcelltransplantconditioningforpatientswithrelapsedlymphomaaretrospectivesinglecenterstudy AT bassimalbeirouti doseadjustedbendamustineasareplacementforcarmustineinautologousstemcelltransplantconditioningforpatientswithrelapsedlymphomaaretrospectivesinglecenterstudy
_version_	1718400919352115200

Dose-adjusted bendamustine as a replacement for carmustine in autologous stem cell transplant conditioning for patients with relapsed lymphoma: A retrospective single-center study

Ejemplares similares